An FDA panel will meet on April 8 to evaluate Bausch + Lomb's Trulign Toric intraocular lens. The company seeks to have the implantable device approved for treating vision impairment in adult patients who have received cataract surgery.
Bausch + Lomb wins FDA date for vision-correcting implant
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||